The present invention provides compounds of Formula (I) as defined in the specification and compositions comprising any of such novel compounds. These compounds are Factor VIIa inhibitors which may be used as medicaments.
[EN] MACROCYCLIC FACTOR VIIA INHIBITORS<br/>[FR] INHIBITEURS DU FACTEUR VIIA MACROCYCLIQUES
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2014201073A9
公开(公告)日:2015-10-08
US9657006B2
申请人:——
公开号:US9657006B2
公开(公告)日:2017-05-23
Design and Synthesis of Novel Meta-Linked Phenylglycine Macrocyclic FVIIa Inhibitors
作者:Jeremy M. Richter、Daniel L. Cheney、J. Alex Bates、Anzhi Wei、Joseph M. Luettgen、Alan R. Rendina、Timothy M. Harper、Rangaraj Narayanan、Pancras C. Wong、Dietmar Seiffert、Ruth R. Wexler、E. Scott Priestley
DOI:10.1021/acsmedchemlett.6b00375
日期:2017.1.12
Two novel series of meta-linked phenylglycine-based macrocyclic FVIIa inhibitors have been designed to improve the rodent metabolic stability and PK observed with the precursor para-linked phenylglycine macrocycles. Through iterative structure-based design and optimization, the TF/FVIIa Ki was improved to subnanomolar levels with good clotting activity, metabolic stability, and permeability.
已经设计了两种新颖的基于间联苯基苯甘氨酸的大环FVIIa抑制剂系列,以改善啮齿动物的代谢稳定性和前体对联苯基苯甘氨酸大环化合物所观察到的PK。通过基于迭代结构的设计和优化,TF / FVIIa K i被提高到亚纳摩尔水平,具有良好的凝结活性,代谢稳定性和通透性。